These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 23980674)

  • 1. Tasquinimod: a novel drug in advanced prostate cancer.
    Osanto S; van Poppel H; Burggraaf J
    Future Oncol; 2013 Sep; 9(9):1271-81. PubMed ID: 23980674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
    Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
    J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
    Schweizer MT; Carducci MA
    Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
    Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
    Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tasquinimod: How to act on microenvironment in metastatic prostate cancer].
    Houédé N; Irani J
    Prog Urol; 2015 May; 25(6):298-305. PubMed ID: 25684391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
    Sternberg C; Armstrong A; Pili R; Ng S; Huddart R; Agarwal N; Khvorostenko D; Lyulko O; Brize A; Vogelzang N; Delva R; Harza M; Thanos A; James N; Werbrouck P; Bögemann M; Hutson T; Milecki P; Chowdhury S; Gallardo E; Schwartsmann G; Pouget JC; Baton F; Nederman T; Tuvesson H; Carducci M
    J Clin Oncol; 2016 Aug; 34(22):2636-43. PubMed ID: 27298414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
    Armstrong AJ; Humeniuk MS; Healy P; Szmulewitz R; Winters C; Kephart J; Harrison MR; Martinez E; Mundy K; Halabi S; George D
    Prostate; 2017 Mar; 77(4):385-395. PubMed ID: 27862097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
    Armstrong AJ; Häggman M; Stadler WM; Gingrich JR; Assikis V; Polikoff J; Damber JE; Belkoff L; Nordle Ö; Forsberg G; Carducci MA; Pili R
    Clin Cancer Res; 2013 Dec; 19(24):6891-901. PubMed ID: 24255071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.
    George S; Pili R
    Curr Oncol Rep; 2013 Apr; 15(2):65-8. PubMed ID: 23334511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
    Dalrymple SL; Becker RE; Isaacs JT
    Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
    Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
    Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
    Bratt O; Häggman M; Ahlgren G; Nordle O; Björk A; Damber JE
    Br J Cancer; 2009 Oct; 101(8):1233-40. PubMed ID: 19755981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials.
    Gong P; Liu H; Liu X; Zhou G; Liu M; Yang X; Xiong W; Wang Q; Ma J; Ren Z; He M; Zhang X
    Medicine (Baltimore); 2018 Nov; 97(46):e13204. PubMed ID: 30431595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
    Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
    Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects.
    Mehta AR; Armstrong AJ
    Ther Adv Urol; 2016 Feb; 8(1):9-18. PubMed ID: 26834836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
    Miller K; Moul JW; Gleave M; Fizazi K; Nelson JB; Morris T; Nathan FE; McIntosh S; Pemberton K; Higano CS
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):187-92. PubMed ID: 23381694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
    Monk P; Liu G; Stadler WM; Geyer S; Huang Y; Wright J; Villalona-Calero M; Wade J; Szmulewitz R; Gupta S; Mortazavi A; Dreicer R; Pili R; Dawson N; George S; Garcia JA
    Invest New Drugs; 2018 Oct; 36(5):919-926. PubMed ID: 30083962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of tasquinimod in the treatment of advanced prostate cancer.
    Williamson SC; Hartley AE; Heer R
    Drug Des Devel Ther; 2013; 7():167-74. PubMed ID: 23662046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.